View Financial HealthMolecular Partners 배당 및 자사주 매입배당 기준 점검 0/6Molecular Partners 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.05%자사주 매입 수익률총 주주 수익률-0.05%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesMolecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712Apr 20Molecular Partners AG Announces Board and Committee AppointmentsApr 15Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-ElectionMar 30Molecular Partners AG, Annual General Meeting, Apr 14, 2026Mar 24Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple IsotopesMar 20New major risk - Share price stability Mar 18Molecular Partners AG to Report First Half, 2026 Results on Aug 25, 2026Mar 14Price target increased by 12% to CHF10.33 Jan 27Molecular Partners AG Announces Formation of Scientific Advisory Board for RadiopharmaceuticalsDec 13Molecular Partners AG Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025Nov 12First half 2025 earnings released: CHF1.02 loss per share (vs CHF0.80 loss in 1H 2024) Aug 26New major risk - Revenue size Aug 26Molecular Partners AG to Report Fiscal Year 2025 Results on Mar 12, 2026Aug 26Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025Aug 21Molecular Partners and Orano Med Present Preclinical Data on Mesothelin-Targeting Radio-DARPin Candidate MP0726 at SNMMI 2025Jun 23New major risk - Share price stability Jun 12Molecular Partners AG Presents Positive Data from Ongoing Phase 1/2a Trial of MP0533 in AML at EHA 2025Jun 12First quarter 2025 earnings released: CHF0.45 loss per share (vs CHF0.34 loss in 1Q 2024) May 16Molecular Partners AG Presents New Preclinical Data on Radio-DARPin and Switch-DARPin Programs at AACR 2025Apr 26Molecular Partners AG, Annual General Meeting, Apr 16, 2025Mar 26Price target increased by 12% to CHF10.50 Mar 17Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn SituationMar 13Price target increased by 7.2% to CHF10.03 Mar 11Full year 2024 earnings released: CHF1.59 loss per share (vs CHF1.89 loss in FY 2023) Mar 09Molecular Partners AG to Report First Half, 2025 Results on Aug 25, 2025Mar 07Consensus revenue estimates fall by 33% Jan 28Molecular Partners AG to Report Q4, 2024 Results on Mar 07, 2025Dec 12Consensus EPS estimates upgraded to CHF1.53 loss Dec 04Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024Nov 08Third quarter 2024 earnings released: CHF0.49 loss per share (vs CHF0.35 loss in 3Q 2023) Nov 01New minor risk - Shareholder dilution Oct 29Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.Oct 26Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.Oct 25We're Keeping An Eye On Molecular Partners' (VTX:MOLN) Cash Burn RateSep 10Consensus revenue estimates decrease by 62%, EPS upgraded Sep 02Second quarter 2024 earnings released: CHF0.46 loss per share (vs CHF0.49 loss in 2Q 2023) Aug 27Price target decreased by 9.7% to CHF9.35 Jul 18Price target increased by 11% to CHF10.35 Jun 25Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3Jun 13Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024Jun 02First quarter 2024 earnings released: CHF0.34 loss per share (vs CHF0.45 loss in 1Q 2023) May 19Insufficient new directors May 01Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of ActionApr 30Consensus revenue estimates fall by 45% Apr 19We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO CompensationApr 11Full year 2023 earnings released: CHF1.89 loss per share (vs CHF3.63 profit in FY 2022) Mar 15Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024Mar 15Consensus revenue estimates fall by 29% Mar 05Molecular Partners AG, Annual General Meeting, Apr 17, 2024Feb 07Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?Jan 09Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024Jan 08Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual MeetingDec 11Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingNov 04New major risk - Share price stability Nov 03Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and ExpositionNov 02Third quarter 2023 earnings released: CHF0.35 loss per share (vs CHF0.41 loss in 3Q 2022) Oct 27Consensus revenue estimates decrease by 40% Sep 29Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn SituationSep 08Second quarter 2023 earnings released: CHF0.49 loss per share (vs CHF0.14 loss in 2Q 2022) Aug 25Molecular Partners AG Announces Executive ChangesAug 25Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023Jun 23Consensus revenue estimates fall by 12% Jun 23First quarter 2023 earnings released: CHF0.45 loss per share (vs CHF4.74 profit in 1Q 2022) May 13Consensus revenue estimates decrease by 73%, EPS upgraded Mar 16Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 10Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid LeukemiaJan 16Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AMLDec 13Price target decreased to CHF12.87 Nov 16High number of new directors Nov 16Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid TumorsNov 11Third quarter 2022 earnings released: CHF0.41 loss per share (vs CHF0.38 loss in 3Q 2021) Oct 28Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-EndOct 28+ 2 more updatesInvestor sentiment improved over the past week Oct 03Consensus forecasts updated Sep 01What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade TodayAug 31Second quarter 2022 earnings released: CHF0.14 loss per share (vs CHF0.56 loss in 2Q 2021) Aug 29Price target increased to CHF30.57 Aug 27Molecular Partners AG, Annual General Meeting, Apr 04, 2023Aug 26+ 1 more updateJohnson Fistel Files A Class Action Complain Against Molecular Partners AGAug 13Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2Jul 22Price target increased to CHF30.57 Jul 20Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – MolnJul 13Investor sentiment improved over the past week Jun 20First quarter 2022 earnings: EPS and revenues miss analyst expectations May 14Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth PlansMay 09Price target decreased to CHF26.83 Apr 27High number of new directors Apr 27Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 17Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19Feb 11Price target increased to CHF27.58 Jan 14Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19Jan 10Forecast to breakeven in 2022 Jan 05Price target decreased to CHF25.00 Dec 30Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) ForecastsDec 26Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical StudiesDec 13지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 MOLN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: MOLN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Molecular Partners 배당 수익률 vs 시장MOLN의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (MOLN)n/a시장 하위 25% (CH)2.0%시장 상위 25% (CH)3.6%업계 평균 (Biotechs)2.3%분석가 예측 (MOLN) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 MOLN 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 MOLN 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 MOLN 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: MOLN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YCH 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/03 14:35종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Molecular Partners AG는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert BurnsH.C. Wainwright & Co.Richard VosserJ.P. MorganWei ChangLeerink Partners LLC4명의 분석가 더 보기
Molecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712Apr 20
Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-ElectionMar 30
Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple IsotopesMar 20
Molecular Partners AG Announces Formation of Scientific Advisory Board for RadiopharmaceuticalsDec 13
Molecular Partners AG Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025Nov 12
Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025Aug 21
Molecular Partners and Orano Med Present Preclinical Data on Mesothelin-Targeting Radio-DARPin Candidate MP0726 at SNMMI 2025Jun 23
Molecular Partners AG Presents Positive Data from Ongoing Phase 1/2a Trial of MP0533 in AML at EHA 2025Jun 12
Molecular Partners AG Presents New Preclinical Data on Radio-DARPin and Switch-DARPin Programs at AACR 2025Apr 26
Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024Nov 08
Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.Oct 26
Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.Oct 25
Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3Jun 13
Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024Jun 02
Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of ActionApr 30
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO CompensationApr 11
Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual MeetingDec 11
Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual MeetingNov 04
Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and ExpositionNov 02
Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid LeukemiaJan 16
Molecular Partners AG Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AMLDec 13
Molecular Partners AG Presents Positive Interim Safety and Mechanistic Data from Ongoing Phase 1 Trial of MP0317 for Treatment of Solid TumorsNov 11
Molecular Partners AG Announces Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-EndOct 28+ 2 more updates
Molecular Partners AG Announces Publication in Nature Biotechnology Detailing Design and Mechanism of Ensovibep DARP in Antiviral for SARS-CoV-2Jul 22
Pomerantz Law Firm Announces the Filing of A Class Action Against Molecular Partners Ag and Certain Officers and Directors – MolnJul 13
Molecular Partners AG Announces Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of Covid-19Feb 11
Novartis and Molecular Partners Report Positive Topline Data from Phase 2 Study for ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19Jan 10
Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) ForecastsDec 26
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical StudiesDec 13
